Resources

Resources from us to you. Right at your fingertips.

Development of Long-Acting Injectable Microspheres

Read more

CRS Nanosuspension Formulation Presentation

Our team presents the process of Nanosuspension for the novel Indirubin, for the potential treatment of Glioblastoma.

Read more

PODD: Partnerships in Drug Delivery

Pharma, biotech and the drug delivery industries gather annually at PODD to assess delivery needs, latest trends and information on deals and learn about a wide range of innovative drug delivery technologies that could improve the delivery of various types of drugs. This can include proteins, peptid

Read more

Webinar | Case Study: Development of Nanoparticles for the Systemic Delivery of Antisense Oligonucleotides to the Central Nervous System

Phosphorex's director of nucleic delivery presents on Nanoparticles for the delivery of ASO to the CNS

Read more

Webinar | A Case Study: Nanoparticle Formulation Enables Systemic Delivery of a Therapeutic Agent to Treat Glioblastoma

In collaboration with Brown University, Phosphorex presents on the use the nanoparticle formulation, to enable Systematic Delivery of Tx Agent to treat GBM

Read more

Phosphorex Expands Leadership Team: Appoints David Tammaro as Chief Financial Officer

Phosphorex, an Ampersand Capital Partners company, and drug delivery-focused contract development and manufacturing organization ("CDMO"), announced today the appointment of David Tammaro as Chief Financial Officer.

Read more

Phosphorex Appoints Jarlath Keating as Chief Executive Officer

Following the recent growth capital investment from Ampersand Capital Partners, Phosphorex announced today the appointment of Jarlath Keating as Chief Executive Officer.

Read more

Phosphorex to Establish cGMP Manufacturing for Lipid Nanoparticles with Growth Capital from Ampersand

Phosphorex, a drug delivery-focused contract development and manufacturing organization providing microspheres and polymer and lipid nanoparticles, today announced a majority recapitalization by Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the health

Read more

Phosphorex and Dolomite Jointly Publish Articles to Discuss How Automation Benefits Development and Production of Lipid Nanoparticles (LNPs)

ONdrugDelivery article to discuss how automation of Lipid Nanoparticles production can benefit the development and manufacture of RNA-based drugs and vaccines.

Read more

Phosphorex and Dolomite Host Collabarative Webinar to Share Their Insights on Making Liposomes and Lipid Nanoparticles (LNPs) with Microfluidics

Phosphorex & Dolomite experts share their insights about the most important considerations when making liposomes and lipid nanoparticles (LNPs) with microfluidics.

Read more

Phosphorex Presents Its Nanosuspension Formulation at CRS Meeting

Phosphorex Presents Its Nanosuspension Formulation at Controlled Release Society Annual Meeting

Read more

Phosphorex and Dolomite Microfluidics Partner to Accelerate Lipid Nanoparticle (LNP) Development

Partnership Creates A Powerful Platform for Pharmaceutical Company Clients.

Read more

Phosphorex Expands Facilities

Phosphorex announced today the acquisition of new laboratory and office space in Hopkinton, MA to meet the increasing demand for its products and services.

Read more

Phosphorex Technologies Showcased at Partnership Opportunities in Drug Delivery (PODD)

AstraZeneca Highlights Collaboration with Phosphorex on use of Zetafinity® Technology to More Effectively Target Immune Cells

Read more

Pharma Talk Radio Podcast, Future Outlook for Novel Drug Delivery

Partnership Opportunities in Drug Delivery (PODD) conference explores the value of drug delivery technologies both to patients and pharma with a focus on the future direction of the field.

Read more